VCYT
NASDAQ HealthcareVeracyte, Inc. - Common Stock
Diagnostics & Research
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
๐ Market Data
| Price | $33.09 |
|---|---|
| Volume | 455,148 |
| Market Cap | 2.64B |
| Beta | 1.960 |
| RSI (14-Day) | 53.2 |
| 200-Day MA | $35.52 |
| 50-Day MA | $33.40 |
| 52-Week High | $50.71 |
| 52-Week Low | $22.61 |
| P/E Ratio | 40.35 |
| Forward P/E | 18.75 |
| Price / Book | 2.01 |
๐ฏ Investment Strategy Scores
VCYT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (92/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (6/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find VCYT in your text
Paste any article, transcript, or post โ the tool will extract VCYT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.